Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dermavant Sciences

- PMLiVE

Tocagen merges with Forte Biosciences after brain cancer fail

New company will focus on Forte's lead skin disease drug

- PMLiVE

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

Realm toppled by second mid-stage trial flop

The hypochlorous acid gel failed to show EASI score improvement compared to placebo

- PMLiVE

GSK sells eczema and psoriasis drug to Dermavant for £250m

The British group is selling off assets outside core therapy areas to boost R&D

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

Research Partnership

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis

You can probably remember at least one of your friends in school who was always scratching and suffered from red, scaly skin rashes, perhaps on their elbows or backs of...

Research Partnership

Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. The report consists of 45-minute quantitative and 30-minute qualitative...

Research Partnership

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers  in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD...

Research Partnership

Novartis building

Novartis adds oral eczema drug with Ziarco acquisition

Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links